Form 4: Relmada Therapeutics Director Casamento Acquires and Forfeits Stock Options

Director Charles J. Casamento acquired and simultaneously forfeited stock options in Relmada Therapeutics on May 24, 2024, under the company's equity incentive plan.

Summary

• On May 24, 2024, Charles J. Casamento, a director of Relmada Therapeutics, acquired options to purchase 20,976 shares of common stock at an exercise price of $2.48 per share.
• These options were granted under the terms of a previous option award from December 15, 2023, due to available shares under the 2021 Equity Incentive Plan.
• On the same day, Casamento voluntarily forfeited these 20,976 options back to the company.
• The forfeited options will be reallocated to holders of similar awards who are not executive officers or directors of Relmada Therapeutics.
• Following these transactions, Casamento directly owns 52,498 stock options and 31,522 stock options.

Sentiment

Score: 6

Explanation: The document describes a routine transaction involving stock options. The sentiment is neutral as it reflects standard equity management practices.

Positives

• The reallocation of forfeited options to non-executive and non-director award holders could be seen as a positive move for employee morale and retention.
• The forfeiture demonstrates a willingness by the director to redistribute equity to other stakeholders.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Management Comments

• Charles J. Casamento voluntarily forfeited the options to allow reallocation to other award holders.

Industry Context

This filing reflects standard practices for equity compensation and adjustments within publicly traded companies. Option grants and forfeitures are common mechanisms for aligning management and employee incentives with shareholder value.

Comparison to Industry Standards

• Equity compensation is a common practice among publicly traded companies, particularly in the biotechnology sector, to incentivize employees and align their interests with those of shareholders.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize stock options and equity incentive plans as part of their compensation packages.
• The specific terms of the option grants, such as the exercise price and vesting schedule, are generally determined based on industry benchmarks and company-specific factors.

Stakeholder Impact

• The reallocation of forfeited options may positively impact non-executive and non-director employees who receive them.
• Shareholders are indirectly affected by the company's equity compensation practices, which aim to align employee incentives with shareholder value.

Key Dates

Keywords

stock options, Relmada Therapeutics, director, equity incentive plan, forfeiture, Casamento, RLMD